

## Materials and Methods

**Preparation and Characterization of Bovine Fibrinogen E<sub>5</sub> Fragment.** A 45-kDa fragment E was purified from a 2-h plasmic digest of bovine fibrinogen as described (1, 2). This fragment was denoted as E<sub>3</sub> because its NH<sub>2</sub> termini (A $\alpha$ Leu-23 or Gln-27, B $\beta$ Lys-61 and  $\gamma$ Tyr-1) determined by NH<sub>2</sub>-terminal sequence analysis by using a Hewlett-Packard G1000S sequenator were equivalent to those reported for human fibrinogen E<sub>3</sub> fragment (3). Further digestion of bovine E<sub>3</sub> fragment with chymotrypsin (Calbiochem) resulted in the appearance of two new discrete fragments with molecular masses of 40 and 35 kDa, denoted as E<sub>4</sub> and E<sub>5</sub>, respectively (Fig. 1*d*). This digestion was performed at room temperature in 20 mM Tris buffer, pH 7.4/0.15 M NaCl. The protein concentration was 2 mg/ml and the enzyme/substrate ratio was 1:100 (wt/wt). The E<sub>5</sub> fragment was purified from a 10-h digest by size-exclusion chromatography by using a 2.5  $\times$  110-cm column with Biogel P60, dialyzed against 25 mM imidazole buffer, pH 6.5, concentrated to 15-20 mg/ml by ultrafiltration by using YM 10 membrane (Amicon), and stored at -20°C.

The NH<sub>2</sub>-terminal sequence analysis of E<sub>5</sub> revealed that the NH<sub>2</sub> termini of its B $\beta$  and  $\gamma$  chains were essentially the same as in E<sub>3</sub>, whereas those for the A $\alpha$  chains starting at Ser-29 were different. To determine the complete sequence of E<sub>5</sub>, this fragment was reduced and derivatized by the method described earlier (4), the chains were separated by HPLC on a reverse-phase Nucleosil C-18 column, and individual chains were digested with trypsin, endopeptidase Lys-C, or CNBr. The resulting peptides were purified by HPLC and sequenced through the end. The complete sequence of E<sub>5</sub> is presented in Fig. 1*c*. Comparison of its NH<sub>2</sub> and COOH termini with those established for the human fibrinogen E<sub>3</sub> fragment (3) revealed that the generation of E<sub>5</sub> is due to the removal of NH<sub>2</sub>-terminal residues 23-28 from the A $\alpha$  chain and several residues from the COOH termini of the B $\beta$  and  $\gamma$  chains. A substantial decrease in the molecular mass of the E<sub>5</sub> fragment can be explained by the removal of two carbohydrates linked to Asn-52 of each  $\gamma$  chain; the intermediate E<sub>4</sub> fragment contains, most probably, one carbohydrate, whereas the other one is removed.

**Crystallization.** Crystals of the E<sub>5</sub> fragment were grown by the vapor-diffusion method in hanging or sitting drops. Drops containing 2-3  $\mu$ l of protein (at 10 mg/ml) and the same volume of well solution [15.0% polyethylene glycol (PEG) 3350/150 mM CaCl<sub>2</sub>/3.5% dioxane/3mM NaN<sub>3</sub>, in 20 mM Tris•HCl, pH 8.0] were mixed and equilibrated against 0.5 ml of the reservoir well solution. Two crystal forms of different morphologies grew at room temperature in 2-4 days in these conditions. Bipyramidal-shaped crystals grew to a size of ~0.2 mm  $\times$  0.3 mm  $\times$  0.6 mm and belong to the orthorhombic space group P2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> with unit cell dimensions of  $a = 53.4$  Å,  $b = 58.8$  Å, and  $c = 96.8$  Å. In addition, needle-shaped crystals grew to ~0.03 mm  $\times$  0.05 mm  $\times$  0.3 mm, and occasionally large rod-shaped crystals grew to ~0.6 mm  $\times$  0.6 mm  $\times$  1.0 mm. These crystals belong to the monoclinic space group P2<sub>1</sub>, and the large rod-shaped crystals have unit cell dimensions

of  $a = 49.4 \text{ \AA}$ ,  $b = 66.2 \text{ \AA}$ , and  $c = 50.7 \text{ \AA}$  with  $\beta = 106.6^\circ\text{C}$ . (Under similar crystallization conditions, but at  $4^\circ\text{C}$ , bar-shaped crystals grew to  $0.2 \text{ mm} \times 0.2 \text{ mm} \times 0.4 \text{ mm}$  after 3–4 weeks. These crystals belong to the same monoclinic space group as those obtained at room temperature.) Crystals were transferred into a cryoprotectant solution (30% PEG 3350/10% glycerol/150 mM  $\text{CaCl}_2$ /3.5% dioxane/3 mM  $\text{NaN}_3$ , in 20 mM Tris•HCl, pH 8.0), flash-cooled in liquid propane, and stored in liquid nitrogen until data collection.

The orthorhombic crystals were used for the search of heavy atom derivatives, as they usually grew faster and bigger and were easier to handle than the monoclinic crystals. After the screening of a number of different heavy atom compounds, a trimethyllead-acetate [ $\text{Pb}(\text{CH}_3)_3\text{OAc}$ ] derivative was obtained. The heavy atom compound was dissolved to a final concentration of 23 mM in the cryoprotectant solution that did not contain  $\text{NaN}_3$ . Crystals were transferred into the cryoprotectant solution, soaked with the heavy atom compound for 4 weeks, and then flash-cooled in liquid propane and stored in liquid nitrogen.

**Biochemical Characterization of Crystals of the E<sub>5</sub> Fragment.** To ensure that the E<sub>5</sub> fragment was not modified on crystallization, several crystals were briefly washed in the well solution and dissolved in 20 mM Tris buffer, pH 8.5, sequenced, and tested for the presence of free sulfhydryls. The NH<sub>2</sub>-terminal sequence analysis confirmed that the NH<sub>2</sub> termini of E<sub>5</sub> from the crystals were the same as in the starting material. A test for the presence of free sulfhydryls was performed as described earlier (5). Briefly, the fragment at 1  $\mu\text{M}$  was mixed with 50  $\mu\text{M}$  pyrene-maleimide, a specific reagent for SH groups, and the fluorescence signal was monitored in time at 395 nm in an SLM 8000-C fluorometer. No changes in fluorescence were observed in 30 min, during which the fluorescence of the control protein containing a single SH group changed substantially, indicating no free SH groups in the crystal-derived E<sub>5</sub> fragment.

**Data Collection and Processing.** All data sets were collected at cryotemperature (100 K). In-house diffraction data were collected on the Rigaku (Tokyo) RAXIS-IV image plate detector mounted on the Rigaku RU300B rotating anode X-ray generator ( $\text{CuK}\alpha$  radiation). Higher resolution data sets were collected on beamline X26C at the National Synchrotron Light Source, Brookhaven National Laboratory, New York, and on beamline A1 at the Cornell High Energy Synchrotron Source in Ithaca, NY. Data collection statistics are summarized in Table 1. Data reduction and processing were carried out with the set of programs HKL (6).

**Model Building and Refinement.** The structure was determined first at 3.0- $\text{\AA}$  resolution with the data from the orthorhombic crystals by using a combination of Single Isomorphous Replacement and density modification with the program DM (7) from the CCP4 suite (8). By using the program SOLVE (9), three substitution sites for the  $\text{Pb}(\text{CH}_3)_3\text{OAc}$  derivative were found independently from the data sets collected in the laboratory and at the synchrotron (see Table 1). Refinement of the heavy atom positions, by using the program MLPHARE from the CCP4 program suite (8), however, produced different heavy atom occupancy values for the two sets of data. As a result, we found that the best quality electron density map could be obtained after combining phases from both

sets of data by using the program MLPHARE, followed by density modification with the program DM (final figure of merit 0.72). This map clearly revealed the positions of the six  $\alpha$ -helices of the coiled-coil regions in each half-molecule. The helices were first modeled as poly-Ala by using the program O (10), and their positions were refined with the program package CNS (11). The quality of the electron density map was further improved with the program SIGMAA (12) by combining heavy atom derivative phases with those from the partial helical model and extending the data used to the 1.6-Å resolution limit of the native orthorhombic crystals. At this stage of the refinement, the side chains were assigned in the coiled-coil regions of the model. Multiple cycles of model building (by using the program O) and refinement (by using the program CNS) within the non-coiled-coil central region of the fragment were necessary to complete the model of the E<sub>5</sub> fragment. In the orthorhombic crystal form, the N-terminal residues A $\alpha$ 29-34, A $\alpha$ '29-34, B $\beta$ 61-63, B $\beta$ '61-63,  $\gamma$ 1, and  $\gamma$ '1, and the C-terminal residues A $\alpha$ 79-81, A $\alpha$ '79-81, B $\beta$ 115-116, B $\beta$ '115-116, and (in one monomer only)  $\gamma$ 48 were disordered and not included in the final model.

By using this model, phases for the monoclinic crystal form were determined by molecular replacement by using the program AMORE (13). The structure was refined to 1.4 Å, initially by using ARP (14) and then CNS. Here, the N-terminal A $\alpha$ 29-34, A $\alpha$ '29-34, B $\beta$ 61-63, B $\beta$ '61-63,  $\gamma$ 1-4, and  $\gamma$ '1, and the C-terminal residues A $\alpha$ 78-81, A $\alpha$ '78-81, B $\beta$ 115-116, and B $\beta$ '114 were disordered and not included in the final model. Refinement statistics are summarized in Table 2.

The figures were made with the programs MOLSCRIPT (15), RASTER3D (16, 17), GRASP (18), XTALVIEW (19), and MOLE (Applied Thermodynamics, Hunt Valley, MD).

**The Coiled-Coil Domains of E<sub>5</sub> (Expanded).** The  $\alpha$ -helical coiled-coil domains of E<sub>5</sub>, consisting of residues A $\alpha$ 50-78, B $\beta$ 85-114, and  $\gamma$ 21-48, have two noncanonical structural features. The sequences of coiled coils are characterized by their so-called “heptad repeat,” where every third then fourth residue is usually apolar and close-packed in the core (20); (for review, see ref. 21). In the E<sub>5</sub> fragment, there is one three-residue deletion from the heptad repeat of each chain, located roughly at homologous positions (A $\alpha$ 65, B $\beta$ 100, and  $\gamma$ 36) midway along the coiled-coil domain (Fig. 1). These deletions, or “stutters,” result in local non-close-packed cores as found in certain other coiled coils (22, 23). In the homotrimeric coiled coil of hemagglutinin (24), similar stutters and non-close-packed cores have been described (22, 23). The conservation of the stutter in the three chains of fibrinogen, along with other sequence similarities, is consistent with the evolution of at least part of the molecule from a homotrimeric precursor (25). In addition, there is a proline residue in this stutter region of the B $\beta$  chains at position 99 (Fig. 2). The location of this residue coincides with a bend in the B $\beta$ -chain helix. The degree of bending varies (between ~12 and 18°) in the two halves of the dimer and in the two crystal forms. The stutter and the proline residue are conserved among a number of vertebrate species, suggesting that these features that promote flexibility may be related to the functions of fibrinogen.

**Detailed Description of the Structures of the Six Chains in the Two Central Domains of Fragment E<sub>5</sub> (Expanded).** As seen in the crystal structure of fragment E<sub>5</sub>, the N-terminal portions of the A $\alpha$  (residues 35-49) and B $\beta$  (residues 64-84) chains from each half-molecule (or “monomer”) have distinct structural roles in the formation of the funnel-shaped domain. The segments of the A $\alpha$  chains are located almost entirely within the central plane that bisects the long axis of the molecule (Fig. 4). The most N-terminal residues of the A $\alpha$  chains, Gly-35 and Trp-36, form part of the rim of the funnel-shaped domain. The two chains diverge from one another (from residues 36 to 41) and then converge in a partially helical (residues 43 to 47) and partially extended (residues 48 and 49) conformation, so that they wrap around the B $\beta$  chains.

In contrast to the A $\alpha$  chains, the B $\beta$  chains in the funnel-shaped domain extend along the long axis of the molecule and interact extensively with the coiled-coil domains. The most N-terminal residues of the B $\beta$  chains, 64-69, are in extended conformations and form the remainder of the central cavity’s rim. Residues 64 and 68 of each of the B $\beta$  chains are also stabilized by salt bridges to their respective monomers’ coiled-coil domains at residues A $\alpha$ 60 and A $\alpha$ 53. Residues 70-84 of each B $\beta$  chain form a relatively long loop, in which residues 70-73 and 80-83 form a two-stranded antiparallel  $\beta$ -sheet. This loop extends toward the coiled-coil domain of the opposite half-molecule: B $\beta$  Leu-79 near the reverse turn forms hydrophobic contacts with A $\alpha$ ’Met54, A $\alpha$ ’Leu57, and  $\gamma$ ’Ala26 of the opposite (denoted by ‘) monomer’s coiled-coil domain, and B $\beta$ Asp-78 forms a salt bridge with B $\beta$ ’Arg-64 (the reciprocal contacts occur as well). One face of each loop forms a major portion of the cavity’s internal surface (or walls), whereas B $\beta$ Cys-72 on the opposite face of the loop is disulfide linked to Cys-39 of the A $\alpha$  chain portion of this domain. The cavity’s surface in this domain is unusual in being dominated by uncharged and hydrophobic amino acid side chains (Fig. 8).

Each of the two  $\gamma$  chains in the  $\gamma$ N-domain (residues 1-20), like the B $\beta$  chains of the funnel-shaped domain, also contribute to the formation of a convoluted dimeric interface (Fig. 2). Following residues 4-7, which form short helices, and the disulfide-forming cysteines at positions 8 and 9, residues 10-16 of each  $\gamma$  chain form a loop that, like the longer loops of the B $\beta$  chains, extends toward and interacts with the opposite monomer’s coiled coil. Here,  $\gamma$ Arg-14 forms a salt bridge with B $\beta$ ’Glu-97, and  $\gamma$ Phe-15 makes hydrophobic contacts with  $\gamma$ ’Phe-28, B $\beta$ ’Leu-93, and B $\beta$ ’Val-94. Residues  $\gamma$ 17-21 and  $\gamma$ ’17-21 then fold back toward their respective coiled-coil domains, crisscrossing *en route* at residues  $\gamma$ 19 and  $\gamma$ ’19, which participate in a short antiparallel  $\beta$ -sheet and form the floor of the funnel-shaped cavity described above. The positions of the N-terminal 14 residues of the  $\gamma$  and  $\gamma$ ’ chains are significantly different from one another (Fig. 7); this asymmetry in the  $\gamma$ N domain is stabilized by the disulfide bonds between residues 8 and 9 (Fig. 3d).

**The Locations and Functions of the Central Domains in the Protofibril of Fibrin (Expanded).** The two-stranded protofibril of fibrin formed after reaction with thrombin can now be modeled by taking into account the domain structure of E<sub>5</sub> (Fig. 6). In E<sub>5</sub>, residues A $\alpha$ 35 and A $\alpha$ ’35 (the most N-terminal residues traced) are located within 21 Å

of each other, and weaker electron density seen in the bovine fibrinogen map (26) suggests that the disulfide bond between residues A $\alpha$ 31 and A $\alpha'$ 31 is positioned above the funnel-shaped cavity nearly coinciding with the 2-fold axis of the dimer (dashed lines in Fig. 3a). The two A $\alpha$  GPR knobs (only 10-12 residues away along the sequence at positions 19-21) are thus constrained to be located roughly on the same side of the molecule as the funnel-shaped domain. In a closed half-staggered protofibril of fibrin, we therefore expect that this domain of the E region from one filament would face the two closely situated  $\gamma$ -domain receptor pockets for these knobs on the adjacent filament (Fig. 6a). [Residues B $\beta$ 64 and B $\beta'$ 64 of E<sub>5</sub> (the most N-terminal residues observed for these chains) are located ~35 Å from each other on opposite sides of the funnel-shaped domain, displaced from one another along the long axis of the molecule (Fig. 4)]. Given the current (incomplete) packing models of fibrin, the positions of these B $\beta$  residues are consistent with the binding of the  $\beta$  knobs [each located ~50 residues away along the sequence) to  $\beta$ C-domain receptor pockets within (27) and/or between (28, 29) protofibrils.] The E<sub>5</sub> structure also indicates that the  $\gamma$ N domain would be situated on the exterior side of the two-stranded protofibril and thus be positioned for possibly influencing associations between protofibrils. [Such interactions using the  $\gamma$ N domain, however, have not yet been reported (27)].

1. Medved, L. V., Platonova, T. N., Litvinovich, S. V. & Lukinova, N. I. (1988) *FEBS Lett.* **232**, 56-60.
2. Privalov, P. L. & Medved, L. V. (1982) *J. Mol. Biol.* **159**, 665-683.
3. Olexa, S. A., Budzynski, A. Z., Doolittle, R. F., Cottrell, B. A. & Greene, T. C. (1981) *Biochemistry* **20**, 6139-6145.
4. Litvinovich, S. V., Henschen, A. H., Krieglstein, K. G., Ingham, K. C. & Medved, L. V. (1995) *Eur. J. Biochem.* **229**, 605-614.
5. Brown, R. D. & Matthews, K. S. (1979) *J. Biol. Chem.* **254**, 5128-5134.
6. Otwinowski, Z. & Minor, W. (1997) *Methods Enzymol.* **276**, 307-326.
7. Cowtan, K. D. (1994) *Joint CCP4 and ESF-EACBM Newsletter on Protein Crystallography* **31**, 34-38.
8. Collaborative Computational Project, Number 4 (1994) *Acta Crystallogr. D* **50**, 760-763.
9. Terwilliger, T. C. & Berendzen, J. (1999) *Acta Crystallogr. D* **55**, 849-861.
10. Jones, T. A., Zou, J.-Y., Cowan, S. W. & Kjeldgaard, M. (1991) *Acta Crystallogr. A* **47**, 110-119.

11. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., *et al.* (1998) *Acta Crystallogr. D* **54**, 905-921.
12. Read, R. J. (1986) *Acta Crystallogr. A* **42**, 140-149.
13. Navaza, J. (1994) *Acta Crystallogr. A* **50**, 157-163.
14. Perrakis, A., Morris, R. M. & Lamzin, V. S. (1999) *Nat. Struct. Biol.* **6**, 458-463.
15. Kraulis, P. J. (1991) *J. Appl. Crystallogr.* **24**, 946-950.
16. Bacon, D. J. & Anderson, W. F. (1988) *J. Mol. Graphics* **6**, 219-220.
17. Merritt, E. A. & Murphy, M. E. P. (1994) *Acta Crystallogr. D* **50**, 869-873.
18. Nicholls, A., Sharp, K. A. & Honig, B. (1991) *Proteins* **11**, 281-296.
19. McRee, D. E. (1992) *J. Mol. Graphics* **10**, 44-46.
20. Crick, F. H. C. (1953) *Acta Crystallogr.* **6**, 689-697.
21. Cohen, C. & Parry, D. A. D. (1990) *Proteins Struct. Funct. Genet.* **7**, 1-15.
22. Lupas, A., Müller, S., Goldie, K., Engel, A. M., Engel, A. & Baumeister, W. (1995) *J. Mol. Biol.* **248**, 180-189.
23. Brown, J. H., Cohen, C. & Parry, D. A. D. (1996) *Proteins Struct. Funct. Genet.* **26**, 134-145.
24. Wilson, I. A., Skehel, J. J. & Wiley, D. C. (1981) *Nature (London)* **5796**, 366-373.
25. Doolittle, R. F., Everse, S. J. & Spraggon, G. (1996) *FASEB J.* **10**, 1464-1470.
26. Brown, J. H., Volkmann, N., Jun, G., Henschen-Edman, A. & Cohen, C. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 3907-3912. (First Published March 28, 2000; 10.1073/pnas.080065697)
27. Yang, Z., Mochalkin, I. & Doolittle, R. F. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 14156-14161.
28. Laurent, T. C. & Blombäck, B. (1958) *Acta Chem. Scand.* **12**, 1875-1877.
29. Hantgan, R. & Hermans, J. (1979) *J. Biol. Chem.* **254**, 11272-11281.